Docmode Health Technologies Ltd H1 FY26 – ₹17.85 Cr Revenue, ₹0.09 Cr Loss, 40% Promoter Pledge, and an EduTech-HealthTech Soap Opera
1. At a Glance
₹21.4 crore market cap. ₹68 stock price. Down 23% in one year, up 37% in six months, and emotionally volatile like a medical intern on night duty. Docmode Health Technologies Ltd is one of those SME listings that looks futuristic on the surface—AI, healthcare professionals, digital learning, CME certifications—but bleeds red ink underneath. Latest half-year numbers show ₹17.85 crore revenue with a loss of ₹0.09 crore, which sounds small until you remember this is a company with negative ROE (-21.7%), ROCE (-0.29%), debt of ₹7.45 crore, and 40.3% of promoter shares pledged. Add to that multiple NCD defaults, repeated pledge invocations, promoter selling, and declining promoter holding (now just 30.86%), and suddenly this doesn’t feel like a boring edtech company—it feels like a Netflix docuseries waiting to happen.
Sales are growing long-term (3-year CAGR ~50%), but margins have collapsed, interest costs are chewing through operating profits, and governance headlines are louder than product launches. Curious already? Good. Let’s dissect this patient properly—scalpel out, sarcasm loaded.
2. Introduction – Welcome to the Digital Doctor’s Waiting Room
Docmode Health Technologies Ltd was incorporated in 2017, riding the wave of “digital learning + healthcare = guaranteed success.” The pitch is seductive: doctors are busy, pharma needs engagement, medical knowledge keeps changing, and someone has to bridge the gap. Docmode volunteered.
Fast forward to 2024–25, the company gets listed on NSE Emerge, raises money, launches AI tools, announces tie-ups with prestigious medical bodies—and then quietly starts defaulting on NCD payments. That escalated quickly.
The company today sits at an awkward intersection of healthcare education, SaaS tools, research platforms, and medico-marketing services. In theory, this is a high-quality, high-margin, scalable business. In practice, margins have evaporated, interest coverage is a worrying 0.08, and promoters seem more busy explaining pledge invocations than selling vision.
Is this a misunderstood platform business in temporary pain, or an over-engineered PowerPoint struggling to convert buzzwords into cash? Let’s keep digging. And be honest—when you see “AI-powered clinical decision support” on an SME stock, do you lean forward… or reach for your wallet defensively?
3. Business Model – WTF Do They Even Do?
Docmode does many things. Possibly too many. Think of it as a Swiss Army knife for doctors—useful, but heavy and expensive to maintain.
At the core is DocMode LERN, an online learning platform serving 3.5 lakh+ healthcare professionals. This includes certification programs, CME courses, speaker-led sessions, quizzes, and the “Gapsule” platform connecting pharma companies with doctors for educational initiatives.
Then comes DocMode SURE, a research and survey platform where 15,000+ verified healthcare professionals participate in studies and surveys and earn income. Sounds great—until you realize surveys don’t scale like software unless pharma budgets cooperate.
Next is DocMode KNOW, which helps medico-marketing teams create scientific promotional content, customized learning programs, and CRM solutions. This is essentially B2B services—good cash flow when contracts come, zero glamour when they don’t.
Then there’s DocMode CARE, anchored by the iNutrimon app, used in about 20 hospitals and 50+ standalone healthcare providers. This app manages nutritional records, patient data, and now even kitchen and F&B management. Yes, your diet plan and hospital canteen are now spiritually connected.
Finally, DocMode SHOP, an online store selling books, journals, event passes, memberships, and clinical products. Because why not?
The result? A company that touches everything from AI to diet charts—but struggles to convert complexity into consistent profitability. Does focus matter? Or is diversification the new distraction?
4. Financials Overview – The Numbers Don’t Lie, They Just Sweat
Result Type Lock
The latest official heading clearly states “Half Yearly Results”. So this is HALF-YEARLY RESULTS. Annualised EPS = Latest EPS × 2. Lock applied. No further debate.
Half-Yearly Performance Table (₹ in Crores)
Source table
Metric
Latest H1 FY26 (Sep 2025)
Same H1 FY25 (Sep 2024)
Previous H2 FY25 (Mar 2025)
YoY %
QoQ %
Revenue
17.85
20.42
21.35
-12.6%
-16.4%
EBITDA
0.80
-0.12
-0.55
NA
NA
PAT
-0.09
-0.52
-1.38
82.7%
93.5%
EPS (₹)
-0.29
-1.65
-4.39
NA
NA
Yes, losses have reduced. Yes, EBITDA turned positive. But revenue is shrinking, and interest costs remain stubborn. Improvement or temporary oxygen mask?
